다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of pain research, v.11, 2018년, pp.2221 - 2227
Oswald, Jessica C (UCSD Center for Pain Medicine, La Jolla, CA, USA, Jessica.OswaldEM@gmail.com) , Schuster, Nathaniel M (UCSD Center for Pain Medicine, La Jolla, CA, USA, Jessica.OswaldEM@gmail.com)
AI-Helper
Now that the vascular hypothesis of migraine is no longer the prevailing theory of migraine pathogenesis, there is interest in developing acute migraine treatments that act exclusively on non-vascular targets. There is a large percentage of non-responders to current acute migraine treatments and the...
1 Schulte LH May A The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks Brain 2016 139 Pt 7 1987 1993 27190019
2 May A Schulte LH Chronic migraine: risk factors, mechanisms and treatment Nat Rev Neurol 2016 12 8 455 464 27389092
3 Humphrey PP Feniuk W Perren MJ Beresford IJ Skingle M Whalley ET Serotonin and migraine Ann N Y Acad Sci 1990 600 600 587 598 discussion 598–600 2252337
4 Pietrobon D Moskowitz MA Pathophysiology of migraine Annu Rev Physiol 2013 75 365 391 23190076
5 Akerman S Holland PR Goadsby PJ Diencephalic and brainstem mechanisms in migraine Nat Rev Neurosci 2011 12 10 570 584 21931334
6 Maassenvandenbrink A Reekers M Bax WA Ferrari MD Saxena PR Coronary side-effect potential of current and prospective antimigraine drugs Circulation 1998 98 1 25 30 9665056
7 Visser WH Jaspers NM de Vriend RH Ferrari MD Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients Cephalalgia 1996 16 8 554 559 8980858
8 Dodick D Lipton RB Martin V Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine Headache 2004 44 5 414 425 15147249
9 O’Connor P Gladstone P Oral sumatriptan-associated transmural myocardial infarction Neurology 1995 45 12 2274 2276 8848207
10 Jayamaha JE Street MK Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan Intensive Care Med 1995 21 1 82 83 7560482
11 Abbrescia VD Pearlstein L Kotler M Sumatriptan-associated myocardial infarction: report of case with attention to potential risk factors J Am Osteopath Assoc 1997 97 3 162 164 9107127
12 Bally M Dendukuri N Rich B Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data BMJ 1909 2017 (357)j
13 Raffaelli B Israel H Neeb L Reuter U The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine Expert Opin Pharmacother 2017 18 13 1409 1415 28749698
14 Capi M de Andrés F Lionetto L Lasmiditan for the treatment of migraine Expert Opin Investig Drugs 2017 26 2 227 234
15 Negro A Koverech A Martelletti P Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential J Pain Res 2018 11 515 526 29563831
16 Vila-Pueyo M Targeted 5-HT 1F Therapies for Migraine Neurotherapeutics 2018 15 2 291 303 29488143
17 Nelson DL Phebus LA Johnson KW Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan Cephalalgia 2010 30 10 1159 1169 20855361
18 Goadsby PJ Classey JD Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input Neuroscience 2003 122 2 491 498 14614913
19 Cohen ML Schenck K 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein J Pharmacol Exp Ther 1999 290 3 935 939 10454462
20 Johnson KW Schaus JM Durkin MM 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs Neuroreport 1997 8 9-10 2237 2239 9243618
21 Charles A Advances in the basic and clinical science of migraine Ann Neurol 2009 65 5 491 498 19479724
22 Goadsby PJ Lipton RB Ferrari MD Migraine--current understanding and treatment N Engl J Med 2002 346 4 257 270 11807151
23 Shepheard S Edvinsson L Cumberbatch M Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370 Cephalalgia 1999 19 10 851 858 10668103
24 Markowitz S Saito K Moskowitz MA Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain J Neurosci 1987 7 12 4129 4136 3694267
25 Adham N Bard JA Zgombick JM Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog Neuropharmacology 1997 36 4-5 569 576 9225282
26 Anton F Herdegen T Peppel P Leah JD c-FOS-like immunoreactivity in rat brainstem neurons following noxious chemical stimulation of the nasal mucosa Neuroscience 1991 41 2-3 629 641 1908066
27 Hunt SP Pini A Evan G Induction of c-fos-like protein in spinal cord neurons following sensory stimulation Nature 1987 328 6131 632 634 3112583
28 Goldstein DJ Roon KI Offen WW Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial Lancet 2001 358 9289 1230 1234 11675061
29 CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy [webpage on the Internet] Durham NC Pappas Ventures 2018 Available from: http://www.pappasventures.com/2012/09/18/colucid-pharmaceuticals-details-phase-3-development-strategy-lasmiditan-address-major-unmet-needs-acute-migraine-therapy/ Accessed August 10, 2018
30 Ferrari MD Färkkilä M Reuter U Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial Cephalalgia 2010 30 10 1170 1178 20855362
31 Färkkilä M Diener HC Géraud G Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study Lancet Neurol 2012 11 5 405 413 22459549
32 SAMURAI: Lasmiditan Reduces Pain in Acute Migraine 2018 Available from: https://globenewswire.com/news-release/2016/09/06/869611/0/en/CoLucid-Pharmaceuticals-Announces-Achievement-of-Both-Primary-and-Key-Secondary-Endpoints-in-the-SAMURAI-Phase-3-Pivotal-Trial-of-Lasmiditan-in-Migraine.html Accessed March 19, 2018
33 Lilly Announces Positive Results for Second Phase 3 Study of Lasmidi-tan for the Acute Treatment of Migraine (NYSE:LLY) ; 2018 Available from: https://investor.lilly.com/static-files/15cf1efc-da8f-485c-9001-6ff3b432b129 Accessed March 19, 2018
34 CoLucid Pharmaceuticals Provides Interim Update on GLADIATOR [webpage on the Internet] GlobeNewswire, Inc. 2016 Available from: https://globenewswire.com/news-release/2016/09/19/872772/0/en/CoLucid-Pharmaceuticals-Provides-Interim-Update-on-GLADIATOR.html Accessed August 10, 2018
35 Lipton RB Buse DC Serrano D Holland S Reed ML Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study Headache 2013 53 8 1300 1311 23879870
36 Cameron C Kelly S Hsieh SC Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis Headache 2015 55 Suppl 4 221 235 26178694
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.